Carl Icahn on Cigna’s Express Scripts deal
Carl Icahn speaks by phone with Fox Business about his opposition to Cigna’s acquisition of Express Scripts. He argues that Express Scripts is overvalued and that its pharmacy-benefit-manager rebate model raises drug prices while obscuring fees. Icahn also cites regulatory pressure for more transparent contracts and competition from new healthcare entrants as threats to the business.
Passages
1:57 “The drug prices are higher because companies like Scripps, the PBMs go to these drug companies and they sort of almost intimidate them into giving them big rebates. And so they could go to their clients with it.” Share
Search what Icahn said from Claude, ChatGPT or your own code. See plans